瑞替普酶静脉溶栓治疗急性心肌梗死的临床效果及安全性

Clinical effects and safety of Reteplase intravenous thrombolytic treatment of acute myocardial infarction

目的:观察瑞替普酶静脉溶栓治疗急性心肌梗死的临床效果及安全性。方法:选取52例急性心肌梗死患者作为研究对象,依据随机数字表法将其分成对照组和研究组各26例,对照组采用尿激酶治疗,研究组采用瑞替普酶治疗,比较两组血管再通率、出血率及CKMB峰值时间。结果:(1)研究组血管再通率是92.31%(24/26),明显高于对照组的69.23%(18/26),差异有统计学意义(P<0.05);(2)研究组用药后出血率是3.85%(1/26),明显低于对照组的23.08%(6/26),差异有统计学意义(P<0.05);(3)研究组CK-MB峰值时间是(11.08±1.89)h,明显短于对照组的(12.75±2.61)h,差异有统计学意义(P<0.05)。结论:瑞替普酶静脉溶栓治疗急性心肌梗死,临床效果肯定,且用药安全性较高。

Objective： To observe clinical effects and safety of Reteplase intravenous thrombolysis treatment of acute myocardial infarction. Methods： 52 patients with acute myocardial infarction were selected as the study subjects. They were divided into control group（ n = 26） and study group（ n = 26） according to the random number table method. The control group was treated with conventional Urokinase,while the study group was treated with Reteplase. The vascular recanalization rate,bleeding rate,and CK-MB peak time were compared between the two groups. Results：（ 1） The recanalization rate of the study group was 92.31%（ 24/26）,which was significantly higher than that of the control group（ 69.23%,18/26）,and the difference was statistically significant（ P〈0.05）.（ 2） The bleeding rate after the treatment of the study group was 3.85%（ 1/26）,which was significantly lower than the control group of 23.08%（ 6/26）,and the difference was statistically significant（ P〈0.05）.（ 3） The CK-MB peak time of the study group was（ 11.08±1.89）h,which was significantly shorter than the control group of（ 12.75±2.61） h,and the difference was statistically significant（ P〈0.05）.Conclusions： Reteplase intravenous thrombolysis treatment of acute myocardial infarction is definitely effective with high safety,and it is worth being referred to.